7-epi-nemorosone from Clusia rosea induces apoptosis, androgen receptor down-regulation and dysregulation of PSA levels in LNCaP prostate carcinoma cells

Phytomedicine

Volumn 19, Issue 14, 2012, Pages 1298-1306

  Díaz Carballo, David ^a   Gustmann, Sebastian ^a   Acikelli, Ali Haydar ^a   Bardenheuer, Walter ^a   Buehler, Helmut ^a   Jastrow, Holger ^b   Ergun, Suleyman ^c   Strumberg, Dirk ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

7 epi nemorosone; Akt PKB; Antitumoral activity; AR; Clusia rosea and Clusia grandiflora (Clusiaceae); MEK1 2; Polyisoprenylated benzophenone; Prostate carcinoma; PSA; Signal transduction analysis

Indexed keywords

7 EPI NEMOROSONE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; PLANT EXTRACT; PROPOLIS; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; CLUSIA; CLUSIA ROSEA; CONTROLLED STUDY; CYTOTOXICITY; DRUG ISOLATION; DRUG STRUCTURE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BEES; BENZOPHENONES; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CLUSIA; CYCLINS; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; HUMANS; KALLIKREINS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PHYTOTHERAPY; PLANT EXTRACTS; PROPOLIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

CLUSIA GRANDIFLORA; CLUSIA ROSEA; CLUSIACEAE;

EID: 84870064488     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2012.08.004     Document Type: Article

References (51)

1. I. Agoulnik, and N.L. Weigel Androgen receptor coactivators and prostate cancer Advances in Experimental Medicine and Biology 617 2008 245 255
2. J. Alapont Alacreu, S. Navarro Rosales, A. Budía Alba, F. España Furió, F. Morera Martínez, and J.F. Jiménez Cruz PSA and hK2 in the diagnosis of prostate cancer Actas Urologicas Espanolas 32 2008 575 588
3. G. Attard, J. Richards, and J. de Bono Targeting the androgen receptor signaling pathway in metastatic prostate cancer Clinical Cancer Research 2011 [Epub ahead of print]
4. H. Azuma, T. Sakamoto, S. Kiyama, T. Ubai, Y. Kotake, T. Inamoto, K. Takahara, Y. Nishimura, N. Segawa, and Y. Katsuoka Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer American Journal of Clinical Oncology 31 2008 188 194
5. L. Benbrahim-Tallaa, M.M. Webber, and M.P. Waalkes Mechanisms of acquired androgen independence during arsenic-induced malignant transformation of human prostate epithelial cells Environmental Health Perspectives 115 2007 243 247
6. V. Bittrich, C. Amaral Mdo, S.M. Machado, and A.J. Marsaioli Floral resin of Tovomitopsis saldanhae (Guttiferae) and 7-epi-nemorosone: structural revision Zeitschrift fur Naturforschung C 58 2003 643 648
7. A.V. Bono, R. Montironi, T. Pannellini, F. Sasso, V. Mirone, P. Musiani, and M. Iezzi Effects of castration on the development of prostate adenocarcinoma from its precursor HGPIN and on the occurrence of androgen-independent, poorly differentiated carcinoma in TRAMP mice Prostate Cancer and Prostatic Diseases 11 2008 377 383
8. Y. Chen, C.L. Sawyers, and H.I. Scher Targeting the androgen receptor pathway in prostate cancer Current Opinion in Pharmacology 8 2008 440 448
9. O. Cuesta-Rubio, B.A. Frontana-Uribe, T. Ramirez-Apan, and J. Cardenas Polyisoprenylated benzophenones in Cuban propolis; biological activity of nemorosone Zeitschrift fur Naturforschung 57 2002 372 378
10. F. Dal Piaz, A. Tosco, D. Eletto, A.L. Piccinelli, O. Moltedo, S. Franceschelli, G. Sbardella, P. Remondelli, L. Rastrelli, L. Vesci, C. Pisano, and N. De Tommasi The identification of a novel natural activator of p300 histone acetyltranferase provides new insights into the modulation mechanism of this enzyme Chembiochem 11 2010 818 827
11. V.F. de Castro Ishida, G. Negri, A. Salatino, and M.F.C.L. Bandeira A new type of Brazilian propolis: prenylated benzophenones in propolis from Amazon and effects against cariogenic bacteria Food Chemistry 125 2011 966 972
12. C.M.A. de Oliveira, A.M. Porto, I.V. Bittrich, and A.J. Marsaioli Floral resins of Clusia spp.: chemical composition and biological function Tetrahedron Letters 37 1996 6427 6430
13. C.M.A. de Oliveira, A.M. Porto, I.V. Bittrich, and A.J. Marsaioli Two polyisoprenylated benzo-phenones from the floral resins of three Clusia species Phytochemistry 50 1999 1073
14. R. de Wit Chemotherapy in hormone-refractory prostate cancer BJU International 101 2008 11 15
15. G. Di Lorenzo, R. Autorino, S. Perdona, M. De Laurentiis, M. D'Armiento, G. Cancello, V. Mirone, C. Imbimbo, N. Longo, V. Altieri, G. Tortora, W.D. Figg, and S. De Placido Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study European Urology 52 2007 1020 1027
16. D. Diaz-Carballo, S. Malak, W. Bardenheuer, M. Freistuehler, and H.P. Reusch Cytotoxic activity of nemorosone in neuroblastoma cells Journal of Cellular and Molecular Medicine 12 2008 2598 2608
17. D. Diaz-Carballo, S. Malak, M. Freistuhler, A. Elmaagacli, W. Bardenheuer, and H.P. Reusch Nemorosone blocks proliferation and induces apoptosis in leukemia cells International Journal of Clinical Pharmacology and Therapeutics 46 2008 428 439
18. D. Diaz-Carballo, S. Seeber, D. Strumberg, and R.A. Hilger Novel antitumoral compound isolated from Clusia rosea International Journal of Clinical Pharmacology and Therapeutics 41 2003 622 623
19. D. Diaz-Carballo, K. Ueberla, V. Kleff, S. Ergun, S. Malak, M. Freistuehler, S. Somogyi, C. Kucherer, W. Bardenheuer, and D. Strumberg Antiretroviral activity of two polyisoprenylated acylphloroglucinols, 7-epi-nemorosone and plukenetione A, isolated from Caribbean propolis International Journal of Clinical Pharmacology and Therapeutics 48 2010 670 677
20. J.M. Fitzpatrick, J. Anderson, C.N. Sternberg, N. Fleshner, K. Fizazi, X. Rebillard, L. Dogliotti, G. Conti, I. Turesson, N. James, A. Heidenreich, E. Solsona, V. Guillem, D. Herchenhorn, J. Moul, J. van Moorselaar, L.J. Coetzee, A. Wilson, A. Bamias, R. de Wit, and M. Chrisofos Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach Critical Reviews in Oncology/Hematology 68 Suppl. 1 2008 S9 S22
21. D. Gioeli, B.E. Black, V. Gordon, A. Spencer, C.T. Kesler, S.T. Eblen, B.M. Paschal, and M.J. Weber Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization Molecular Endocrinology 20 2006 503 515
22. R. Graeser, D.E. Chung, N. Esser, S. Moor, C. Schächtele, C. Unger, and F. Kratz Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP) International Journal of Cancer 122 2008 1145 1154
23. F. Holtrup, A. Bauer, K. Fellenberg, R.A. Hilger, M. Wink, and J.D. Hoheisel Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR) British Journal of Pharmacology 162 2011 1045 1059
24. D. Hull, and D.G. Bostwick Androgen deprivation therapy for precancerous lesions of the prostate Best Practice & Research 22 2008 285 291
25. H. Jahnisch, S. Fussel, A. Kiessling, R. Wehner, S. Zastrow, M. Bachmann, E.P. Rieber, M.P. Wirth, and M. Schmitz Dendritic Cell-based Immunotherapy for Prostate Cancer Clinical & Developmental Immunology 2010 2010 517493
26. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA: A Cancer Journal for Clinicians 60 2010 277 300
27. J. Kao, J. Cesaretti, N. Stone, and R. Stock Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity Current Urology Reports 2011 [Epub ahead of print]
28. P. Koivisto, and H. Helin Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma Journal of Pathology 189 1999 219 223
29. K. Kuroda, H. Liu, S. Kim, M. Guo, V. Navarro, and N.H. Bander Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy Prostate 69 2009 1579 1585
30. D.N. Lavery, and C.L. Bevan Androgen receptor signalling in prostate cancer: the functional consequences of acetylation Journal of Biomedicine & Biotechnology 2011 2011 862125
31. B. Mellado, J. Codony, M.J. Ribal, L. Visa, and P. Gascon Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway Clinical & Translational Oncology 11 2009 5 10
32. M. Mikhailova, Y. Wang, R. Bedolla, X.H. Lu, J.I. Kreisberg, and P.M. Ghosh AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer Advances in Experimental Medicine and Biology 617 2008 397 405
33. N. Mottet, J. Bellmunt, M. Bolla, S. Joniau, M. Mason, V. Matveev, H. Schmid, T. Van der Kwast, T. Wiegel, F. Zattoni, and A. Heidenreich EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer European Urology 59 2011 572 583
34. N. Olshavsky, E.M. Groh, C.E. Comstock, L.M. Morey, Y. Wang, M.P. Revelo, C. Burd, J. Meller, and K.E. Knudsen Cyclin D3 action in androgen receptor regulation and prostate cancer Oncogene 27 2008 3111 3121
35. G.L. Pardo-Andreu, Y. Nunez-Figueredo, V.G. Tudella, O. Cuesta-Rubio, F.P. Rodrigues, C.R. Pestana, S.A. Uyemura, A.M. Leopoldino, L.C. Alberici, and C. Curti The anti-cancer agent nemorosone is a new potent protonophoric mitochondrial uncoupler Mitochondrion 11 2011 255 263
36. A. Popolo, A.L. Piccinelli, S. Morello, R. Sorrentino, C.R. Osmany, L. Rastrelli, and P. Aldo Cytotoxic activity of nemorosone in human MCF-7 breast cancer cells Canadian Journal of Physiology and Pharmacology 89 2011 50 57
37. A. Popolo, A.L. Piccinelli, S. Morello, R. Sorrentino, C.R. Osmany, L. Rastrelli, and A. Pinto Cytoxic activity of nemorosone in human MCF-7 breast cancer cells Canadian Journal of Physiology and Pharmacology 89 2011 149
38. A. Sciarra, G. Mariotti, S. Salciccia, A.A. Gomez, S. Monti, V. Toscano, and F. Di Silverio Prostate growth and inflammation The Journal of Steroid Biochemistry and Molecular Biology 108 2008 254 260
39. J. Serkedjieva, N. Manolova, and V. Bankova Anti-influenza virus effect of some propolis constituents and their analogues (esters of substituted cinnamic acids) Journal of Natural Products 55 1992 294 302
40. G. Sinnathamby, J. Zerfass, J. Hafner, P. Block, Z. Nickens, A. Hobeika, A.A. Secord, H.K. Lyerly, M.A. Morse, and R. Philip ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers Clinical and Experimental Immunology 163 2011 324 332
41. G. Sonpavde, and C.N. Sternberg The role of docetaxel based therapy for prostate cancer in the era of targeted medicine International Journal of Urology 17 2010 228 240
42. Sundaram, M.V.; 2006. RTK/Ras/MAPK signaling, WormBook, ed. The C. elegans Research Community, WormBook, http://dx.doi.org/10.1895/wormbook.1.80.1, http://www.wormbook.org.
43. I. Takizawa, T. Nishiyama, N. Hara, E. Isahaya, T. Hoshii, and K. Takahashi Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: tumor malignant potential and androgen milieu Prostate 70 2010 1395 1401
44. E. Tokunaga, E. Oki, A. Egashira, N. Sadanaga, M. Morita, Y. Kakeji, and Y. Maehara Deregulation of the Akt pathway in human cancer Current Cancer Drug Targets 8 2008 27 36
45. M. Tsugita, S. Tsuru, T. Takasaki, N. Shinomiya, S. Kobayashi, and F. Hanyu Flowcytometric measurement of the cell cycle of experimental tumors: some devices for accurate measurement of proliferative activity Oncology 48 1991 343 346
46. I. Vermes, C. Haanen, H. Steffens-Nakken, and C. Reutelingsperger A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V Journal of Immunological Methods 184 1995 39 51
47. M.R. Wilson Apoptosis: unmasking the executioner Cell Death and Differentiation 5 1998 646 652
48. Y. Wu, J.E. Rosenberg, and M.E. Taplin Novel agents and new therapeutics in castration-resistant prostate cancer Current Opinion in Oncology 23 2011 290 296
49. H.L. Zhang, D.W. Ye, X.D. Yao, B. Dai, S.L. Zhang, Y.J. Shen, Y. Zhu, and W. Zhang Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center Urologia Internationalis 79 2007 307 311
50. Q. Zhang, and J.A. Porco Jr. Total synthesis of (±)-7-epi- nemorosone Organic Letters 14 2012 1796 1799
51. M. Zhu, and N. Kyprianou Androgen receptor and growth factor signaling cross-talk in prostate cancer cells Endocrine-related Cancer 15 2008 841 849